NH001-2: Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury
Study Details
Study Description
Brief Summary
The purpose of this study is to test the drug apomorphine in subjects who are in a Vegetative State or a Minimally Conscious State.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
This is a prospective, multi-center, randomized, double-blind, placebo-controlled study of the safety and efficacy of NH001 to improve the functional outcome of patients in a vegetative state or minimally conscious state following a severe traumatic brain injury (TBI).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Apomorphine Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day. |
Drug: Apomorphine
Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
|
Placebo Comparator: Placebo Patients will receive a continues subcutaneous infusion of saline solution. |
Drug: Placebo
Patients will receive a continues subcutaneous infusion of saline solution.
|
Outcome Measures
Primary Outcome Measures
- Presence or absence of meaningful responses to external commands based on Coma Recovery Scale-Revised [Day 42 or the day that the drug treatment is discontinued, whichever happens earlier.]
Secondary Outcome Measures
- Coma/Near Coma Scale (CNC) Disability Rating Scale (DRS), Glasgow Outcome Scale Extended (GOS-E), ability to participate in 3 hours a day of active rehabilitation, and a clinical impression of change. [Baseline, weekly during drug treatment and at follow up visits of days 90,180 and 360.]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient is between 18 and 50 years of age, inclusive.
-
Male or non-pregnant female (females of child-bearing potential will be required to have undergone a pregnancy test with negative results prior to entry to the study).
-
Patients will have sustained a severe closed head injury within one to four months.
-
Patients will have remained in a vegetative or minimally conscious state between one and four months after injury.
-
Patients will have reached a stabilized clinical state prior to admission to the study (e.g. afebrile, haemodynamic and electrolyte stability).
-
Patients will have a mean DRS score between 17 and 29, when measured twice a day over two consecutive days.
-
Informed consent from a legal representative will have been obtained, according to the procedures outlined in Section 8.1.2.
-
Patients who, according to the investigator's opinion, are likely to be available for the required 180-day follow up evaluation.
Exclusion Criteria:
-
Patients who are not clinically stable at the time of entry into the study (infections, cardiovascular decompensation, etc.)
-
Patients who require mechanical respiratory assistance.
-
Patients who show signs of progressive neurological deterioration post-TBI.
-
Patients with a known history of medically relevant substance abuse.
-
Patients with history of cardiac disease.
-
Patients who suffered an anoxic event.
-
Patients who have received an investigational drug within 30 days of the study.
-
Patients who have previously used NH001, other dopaminergic agent (e.g. levodopa, amantadine, domperidone) or any known neuro-stimulant (e.g. methylphenidate, amphetamines, atomoxetine, modafinil) within the last 7 days days.
-
Patients who are receiving dopamine blockers (e.g. risperidone, haloperidol, chlorpromazine, flupenthixol, clozapine, olanzapine, quetiapine)
-
Patients who are receiving drugs of the 5HT3 antagonist class, including, for example, ondansetron, granisetron, dolasetron, palonosetron and alosetron.
-
Patients who are receiving tricyclic antidepressants drugs
-
Patients who are receiving type I antiarrhythmics (i.e. quinidine).
-
Patients who have a known history of cardiac arrhythmias or congenital QTc prolongation.
-
Patients who have a known history of previous neurological functional impairment (e.g. stroke, spinal cord injury, dementia, epilepsy, psychiatric diseases).
-
Patients who experienced seizures within the first week post injury or have ongoing seizures.
-
Patients receiving prophylactic anti-convulsive medications.
-
Patients with known allergies to apomorphine, morphine, sulfites or trimethobenzamide.
-
Patients who are receiving nitrates or other vasodilators.
-
Patients receiving CNS acting agents such as barbiturates, morphine, belladonna, opiates.
-
For male patients, patients who are receiving trazodone or any other drug that is known to produce priapism.
-
Patients without a relative or legal guardian to consent to the study.
-
Patients who, according to the investigator's opinion, are unlikely to be available for the required 180-day follow up evaluation.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Spaulding Rehabilitation Hospital | Boston | Massachusetts | United States | 02114 |
Sponsors and Collaborators
- NeuroHealing Pharmaceuticals Inc.
- FDA Office of Orphan Products Development
Investigators
- Principal Investigator: Elkan R Gamzu, PhD, NeuroHealing Pharmaceuticals Inc.
- Principal Investigator: Ross D Zafonte, DO, Spaulding Rehabilitation Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 3337